================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Act of 1934
Date of Report (Date of earliest event reported): September 16, 2002
MEDITECH PHARMACEUTICALS, INC.
------------------------------
(Exact name of registrant as specified in its charter)
NEVADA 0-12561 95-3819300
------ ------- ----------
(State or other (Commission (I.R.S. Employer
jurisdiction File Number) Identification No.)
of incorporation)
10105 E. Via Linda, #103 (PMB 382)
Scottsdale, Arizona 85258
------------------- -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (480) 614-2874
================================================================================
ITEM 5. OTHER EVENTS.
On September 16, 2002, the Registrant issued a press release announcing
that it had entered into a binding memorandum of understanding with P&P Research
of Seoul, South Korea. A copy of the press release is attached hereto as Exhibit
99.1
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
Exhibit Name of Exhibit
------- ---------------
10.5 Memorandum of Understanding dated September
12, 2002 between Meditech Pharmaceuticals,
Inc and P&P Research, Inc.
99.1 Press release of Registrant dated
September 16, 2002.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
MEDITECH PHARMACEUTICALS, INC.
Date: September 16, 2002 By: /s/ Gerald Kern
--------------------------------
Gerald Kern,
Chief Executive Officer